Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies

Table 1 Summary of studies which assessed the current main epidermal growth factor receptor targeted drugs for non small cell lung cancer

Study	Molecule	Place of study	EGFR positive selectedmutations	No. ofpatients	Clinical stage	Responserate (%)	Median OS(mo)	Median PFS(mo)
Kris et al, 2003	Gefitinib	United States	No	221	IIIB and IV	22	6-7	-
Perez-Soler et al, 2004	Gefitinib	United States	No	57	IIIB and IV	12.3	8.4	-
Maemondo et al, 2010	Gefitinib	Asia	Yes	230	IIIB and IV	73.7	30.5	10.8
Mok et al, 2009	Gefitinib	Asia	No	609	III and IV	71.2	18.6	5.7
Mitsudomi et al, 2010	Gefitinib	Japan	yes	177	IIIB and IV	62.1	30.9	9.2
Shepherd et al, 2005	Erlotinib	America, Europe and Asia	No	731	IIIB and IV	8.9	6.7	2.2
Herbst et al, 2005	Erlotinib	United States	No	526	IIIB and IV	30	10.6	6
Capuzzo et al, 2010	Erlotinib	Italy	yes	437	IIIB and IV	11.9	12.3	12.3

EGFR: Epidermal growth factor receptor; OS: Overall survival; PFS: Progression-free survival.